Befovacimab

DB16188InvestigationalProtein Based Therapies

Befovacimab: Overview.

Mechanism
Curator reviewed
Also known as
Human tissue factor pathway inhibitor-neutralizing antibody (bay 1093884) · Immunoglobulin g2, anti-(human tissue factor pathway inhibitor) (human monoclonal 1093884 .gamma.2-chain), disulfide with human monoclonal 1093884 .lambda.-chain, dimer
Code names
BAY-1093884

Resolves to

Compound
UNII8FFQ0L4R3BCAS2156634-62-5
Targets
P10646TFPI

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Befovacimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In